Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Acquisitions: 2015-2020

  • Aytu Biopharma's Acquisitions was N/A to $5.5 million in Q2 2020 from the same period last year, while for Jun 2020 it was $532,393, marking a year-over-year change of. This contributed to the annual value of $15.7 million for FY2021, which is 168.75% up from last year.
  • Latest data reveals that Aytu Biopharma reported Acquisitions of $5.5 million as of Q2 2020, which was up 201.34% from -$5.4 million recorded in Q2 2017.
  • In the past 5 years, Aytu Biopharma's Acquisitions registered a high of $5.5 million during Q2 2020, and its lowest value of -$5.4 million during Q2 2017.
  • Over the past 1 years, Aytu Biopharma's median Acquisitions value was $5.5 million (recorded in 2020), while the average stood at $5.5 million.